Product Description
AKL Research and Development is developing Apocynin as a treatment for osteoarthritis of the knee. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04657926)
Mechanisms of Action: NOX Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AKL Research and Development
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoarthritis, Knee
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-508791-11-00 |
2023-508791-11-00 | P2 |
Active, not recruiting |
Osteoarthritis, Knee |
2025-04-01 |
2025-05-02 |
Treatments |